CWT-004 for Wound Healing
As we get older, our capacity for skin healing becomes impaired, representing a significant unmet clinical need and a barrier to healthy ageing. The incidence of non-healing skin wounds is estimated to be more than 5-7million in the US alone, costing over $25 Billion per year to treat [1]. To target this Causeway, in partnership with Dr Andrea Caporali at the University of Edinburgh, is developing a miR-148b replacement therapy. Work published by Dr Caporali’s group showed that wounds treated with miR-148b healed faster and more completely compared to placebo controls [2]. A miR-148b based therapy has the potential to enhance the healing of diabetic foot ulcers but also wounds more generally.
1. Sen, C.K., et al. (2009) Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair Regen. 17(6):763–771
2. Miscianinov, V. et al. (2018). MicroRNA-148b Targets the TGF-β Pathway to Regulate Angiogenesis and Endothelial-to-Mesenchymal Transition during Skin Wound Healing. Molecular Therapy. 26 (8), p1-12.
1. Sen, C.K., et al. (2009) Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair Regen. 17(6):763–771
2. Miscianinov, V. et al. (2018). MicroRNA-148b Targets the TGF-β Pathway to Regulate Angiogenesis and Endothelial-to-Mesenchymal Transition during Skin Wound Healing. Molecular Therapy. 26 (8), p1-12.
